Calibration for Success: Why Physician Preference Items Require More Than Physician Preference

Many emerging medical device companies operate on a quiet but consequential assumption: if a product is innovative enough, physician preference will carry it through the health system on its own. In reality, Physician Preference Items (PPIs) succeed when their value proposition is deliberately calibrated to each stakeholder who influences the adoption decision — not simply the surgeon who prefers it.

Innovation alone rarely wins. Alignment does.

The Surgeon: Clinical Confidence and Patient Outcomes

Physicians remain the primary champions of most PPIs, and their advocacy is genuinely necessary — but they evaluate new technology strictly through a clinical lens. The questions that matter to them are direct.

• Does the device improve patient outcomes?
• Does it reduce procedural risk?
• Is it intuitive and easy to use?
• Does it create greater consistency or efficiency in the procedure?

Clinical evidence and physician advocacy are essential. But in a health system's broader adoption process, they are only the opening argument — one piece of a much larger equation.

The OR and Perioperative Leadership Team: Operational Performance

OR directors and perioperative leaders evaluate a new technology through an entirely different lens: operational impact. Their questions typically center on the same handful of concerns.

• Will this improve OR efficiency and patient throughput?
• Does the technology benefit both the surgeon and the broader OR team?
• Will implementation create workflow challenges, or will it simplify existing processes?
• Is there an opportunity to standardize the solution across additional physicians?

Perhaps most consequential of all: are these leaders willing to align with the physician champion when the conversation moves to Supply Chain and the Value Analysis Committee (VAC)? Their support is frequently the bridge between physician enthusiasm and organizational adoption — and without it, that enthusiasm rarely travels far.

Supply Chain: Preparation, Not Just Process

Too many device companies treat Supply Chain as the final hurdle in the adoption process — a box to check after the clinical case has already been made. The most successful companies engage Supply Chain early, well before a formal proposal is submitted, and treat the relationship as a genuine part of the strategy rather than an approval gate.

Early engagement means answering questions such as these.

• Have the key sourcing and category leaders been engaged directly?
• Do they understand the high-level value proposition in terms that matter to their function?
• Are they already aware of the physician and operational support that has been established?
• Have they provided guidance on the health system's specific PPI pathway and VAC process?

This kind of early engagement builds awareness long before a proposal is formally submitted through platforms such as Lumere or Symplr, and it gives both the manufacturer and the health system time to prepare for a more productive, less adversarial review.

The Value Analysis Committee: Enterprise-Wide Value

By the time a proposal reaches the Value Analysis Committee, the groundwork should already be substantially complete. A VAC presentation that succeeds is one where the answers to the hardest questions are already known.

• Have physician, nursing, and operational stakeholders been aligned in advance?
• Are internal sponsors prepared to participate actively in the discussion?
• Has the enterprise-wide value — not just the departmental value — been clearly articulated?
• How will the technology affect existing contracts and formulary commitments?

Health systems must continually balance the appeal of clinical innovation against the discipline of financial stewardship. Introducing a new device can carry implications well beyond a single physician's preference, particularly in categories where incumbent manufacturers maintain broader, multi-category contractual relationships across the system.

Even a modest change to a PPI formulary can create cascading effects across an entire health system — and whether those effects are seen as an improvement or a setback depends almost entirely on how each stakeholder perceives the value of the change.

---

The Bottom Line: Alignment Is the Strategy

New device companies entering the market must do more than promote product features to the physicians who will use them. They must proactively educate, align, and support every department involved in the evaluation — from the OR to Supply Chain to the boardroom conversation the VAC ultimately has about enterprise risk.

Believing a product will “sell itself” on the strength of its innovation is one of the most common — and most expensive — miscalculations in medical device commercialization. It rarely leads anywhere but frustration and stalled adoption.

The companies that achieve lasting success in this market understand a simple reality: innovation opens the door. Stakeholder alignment is what walks it through.